Veracyte, Inc.

Today, we honor Dr. Martin Luther King Jr.'s powerful legacy of justice and equality, including his passionate advocacy for healthcare access for all. May his vision continue to drive meaningful change and progress in the world, ensuring medical breakthroughs in science reach every community through research, innovation, compassion, and care.     #MLKDay #MLKDay2025 #healthcareequity #healthcareforall #socialjustice #innovation #unity

American Cancer Society’s annual report, Cancer Statistics, 2025, is now out and highlights encouraging progress that has been made in our fight against cancer as well as remaining challenges that persist, including rising incidences of breast cancer and prostate cancer and ongoing healthcare inequalities for underserved communities. Read ACS’s press release: https://lnkd.in/guHw4ShD If you are interested in learning more about Veracyte's tests, we invite you to visit: 🔗 Prosigna Breast Cancer Assay: https://lnkd.in/g3Y4si-B 🔗 Decipher Prostate Genomic Classifier: https://lnkd.in/gWUUSi9b #cancerresearch #cancerstatistics #researchmatters #cancerawareness  #fightcancer #oncology #breastcancer #prostatecancer #healthcareequality #genomictesting #moleculartesting #precisionmedicine 

🎥 We invite you to explore UroToday's Center of Excellence for Decipher Prostate. Leading experts in prostate cancer share their clinical experience with the test as well as their perspectives on the evolving landscape of genomic testing for #prostatecancer care. 🔗 Access the Decipher Prostate Center of Excellence on UroToday: https://lnkd.in/g47KNet2 #ProstateCancer #UrologyCare #GenomicTesting #PersonalizedMedicine #UroToday 

We’re pleased to announce Veracyte has been #GreatPlaceToWork – CertifiedTM in the US and Israel. We’re honored to receive this recognition, reflecting our collaborative culture driving our mission. Thank you for making us who we are #TeamVeracyte!    🔎  Explore our Great Places to Work – Certified Company overview page: https://lnkd.in/gHVfSjpu      🤝  Learn more about our exceptional team and working at Veracyte:   https://lnkd.in/eiuur7cx      #GPTWcertified #employeeappreciation #workculture #lifeatVeracyte #employeeexperience #inspiredworkplace #pioneeringtogether #cultureofexcellence #workinIsrael #innovationculture #creativeecosystem #diverseworkplace  

From our #TeamVeracyte family to yours – thank you for making 2024 extraordinary! 🌟 To our incredible employees who fuel our progress, the physicians who trust our tests, and the partners who work with us to drive insights and evidence – thank you. Together we are transforming cancer care for patients around the world. 🌍 As we welcome 2025, we're grateful for each person who contributes to our mission of improving cancer care with exceptional diagnostics 🤍 Wishing you all moments of joy and meaningful connections this holiday season! #LifeSciences #Healthcare #Diagnostics 

We are grateful to have had the opportunity to work with Dr. Felix Feng on innovative trials and biomarker development. His impact to cancer patients was profound and will be long lived. He will be dearly missed. #ProstateCancerResearch #CancerResearch #Healthcare #Innovation

Thank you, Allison Gatlin and Investor's Business Daily, for your thoughtful coverage of Veracyte's growth story and our mission to improve patient care through innovative diagnostics. 🔗 Read more about how Veracyte is working to transform cancer diagnostics: https://lnkd.in/gtwq4kmv   #DecipherProstate #PrecisionMedicine #CancerDiagnostics #UrologicOncology #MolecularDiagnostics  

Among the nearly 300,000 patients in the United States diagnosed with prostate cancer each year,* those with low-risk characteristics, such as Gleason Grade Group 1 disease, may choose Active Surveillance (AS) where they are monitored without initial treatment to avoid treatment-related complications.       Mark I. Sultan, M.D., a clinical research assistant specialist at University of California Irvine, presented data at the Society of Urologic Oncology (#SUO24) last week showing that Decipher Prostate Genomic Classifier independently predicted prostate cancer progression, relative to multiparametric magnetic resonance imaging (mpMRI), in a large cohort of men with prostate cancer who were being managed with Active Surveillance (AS).     “Our results show that the Decipher Prostate test is an independent predictor of cancer progression in AS regardless of a patient’s risk on mpMRI, meaning that a Decipher test and a prostate mpMRI capture distinct, complementary prognostic information. These findings suggest that, when combined, the tests will provide a more comprehensive assessment of an individual’s cancer.”     Congratulations to Mark Sultan, M.D., and the UC Irvine team on their important research advancing precision medicine in prostate cancer care 👏   For more details on Dr. Sultan's presentation:    🔗 SUO Abstract: https://lnkd.in/gzTwnn9w     🔗 UroToday Coverage: https://lnkd.in/gcGu3Tuz      #UroOnc #PrecisionMedicine #ProstateCancer #ClinicalResearch #LifeSciences     This article contains forward-looking statements. These forward-looking statements involve risks and uncertainties. Please visit our website for more information https://lnkd.in/gpHMFcjH     *American Cancer Society. Cancer Facts & Figures 2024. Atlanta: American Cancer Society, 2024. 

Advancing precision medicine in breast cancer care takes dedication, innovation, and trusted partnerships. This week at #SABCS24, our Veracyte team is proud to showcase how the #Prosigna test is helping clinicians worldwide advance breast cancer treatment decisions. 📍Connect with us at booth #1243 and attend our in-booth focused medical discussions throughout #SABCS24. The full schedule of medical discussions is available at: https://lnkd.in/eEt_UQ9N   #PrecisionMedicine #CancerCare #Oncology #ClinicalResearch #BreastCancer #IntrinsicMolecularSubtypes  

🏆 Milestone achievement: The Decipher Prostate Genomic Classifier is now the only gene expression test with the Simon Level 1 evidence needed to be listed as an advanced tool for risk stratification of localized prostate cancer in the NCCN Clinical Practice Guidelines in Oncology* (NCCN Guidelines®) for prostate cancer. With validation from studies involving over 100,000 patients, this 22-gene test helps to arm physicians with extra information to help them make personalized treatment decisions. 🔗 Read the press release and learn more, https://lnkd.in/g7GdqhKR   *National Comprehensive Cancer Network. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.  #PrecisionMedicine #ProstateCancer #Oncology #DecipherProstate